路透社消息:11月8日,辉瑞以最高100亿美元的价格击败诺和诺德,成功拿下减肥药新星Metsera。这场持续近两个月的收购战,落下帷幕。左右此次收购最重要的因素可能是来自美国联邦贸易委员会(FTC)的监管压力。此前,11月5日,FTC向诺和诺德发出警告信,指出其收购方案可能违反《哈特-斯科特-罗迪诺反垄断改进法》,并可能降低Metsera继续开发药物的动力。Metsera随后表示,诺和诺德的方案...
Source Link路透社消息:11月8日,辉瑞以最高100亿美元的价格击败诺和诺德,成功拿下减肥药新星Metsera。这场持续近两个月的收购战,落下帷幕。左右此次收购最重要的因素可能是来自美国联邦贸易委员会(FTC)的监管压力。此前,11月5日,FTC向诺和诺德发出警告信,指出其收购方案可能违反《哈特-斯科特-罗迪诺反垄断改进法》,并可能降低Metsera继续开发药物的动力。Metsera随后表示,诺和诺德的方案...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.